Thursday, 28 September 2023 | 10:15-11:30 | Conference Centre
The New Pharmaceutical legislation sets out ways to increase availability, access and affordability of medicines (“triple A”).
The European Medicines Agency is already actively implementing the Regulatory Science Strategy and European Medicines Regulatory Network Strategy to 2025. These strategies address the triple A challenge, with increased dialogue with patients and healthcare professionals, HTA and payers, as well as embracing new technologies, influencing and facilitating development of highly innovative medicines and treatment.
Join us for this session to debate with key stakeholders whether regulators are on the right track with the strategies they have set out to enable access and availability of medicines. Share your view on opportunities arising from current significant changes in the European ecosystem and anticipating the impact of the “triple A” political objectives in the new pharma legislation. Debate with us what success looks like in delivering on those!